Skip to main content

Table 1 Clinical characteristics of 124 patients included in the study

From: The outcomes and prognostic factors of patients who underwent reoperation for persistent/recurrent papillary thyroid carcinoma

Variables

Median(range)/number(ratio)

Female

80/ (64.5%)

Age at reoperation

42 (13–73)

Time span between initial surgery and reoperation (months)

16 (5–38)

Pre-reop unstim-Tg (ng/mL)a

11.12 (0.1–1000)

Post-reop unstim-Tg (ng/mL)b

2.04 (0.1–600)

Tg different between pre-/post-reoperation (ng/mL)c

5.03 (− 499.82–999.61)

Frequency of pre-reop RAI therapy

2 (1–8)

Dose of pre-reop RAI therapy (mCi)

250 (50–750)

RAI-avidity character

 Avid

60 (48.4%)

 Refractory

55 (44.4%)

 Unknown

9 (7.2%)

Number of pathologically proven metastatic lymph node at reoperation

4 (1–19)

Largest dimision of positive lymph node (cm)

1.9 (0.4–5)

Metastatic lymph node with extranodal extension

39 (31.4%)

Metastatic lymph node with squamous dedifferentiation

6 (4.8%)

  1. aPre-reop unstim-Tg were performed at the time just before reoperation
  2. bPost-reop unstim-Tg were performed 1–3 months after reoperation
  3. cThe Tg different was calculated by subtracting post-reop unstim-Tg from pre-reop unstim-Tg
  4. Pre-reop pre-reoperative, Post-reop post-reoperative, unstim-Tg unstimulated thyroglobulin, RAI radioiodine, cm centimeter